PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitor...

Full description

Bibliographic Details
Main Authors:	Hyojin Kim, Jin-Haeng Chung
Format:	Article
Language:	English
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology 2019-07-01
Series:	Journal of Pathology and Translational Medicine
Subjects:	Immunotherapy Programmed cell death-ligand 1 Immunohistochemistry Predictive biomarker Carcinoma, non-small cell lung
Online Access:	http://www.jpatholtm.org/upload/pdf/jptm-2019-04-24.pdf

Similar Items

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
by: Yeon Bi Han, et al.
Published: (2019-03-01)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
by: Shumin Li, et al.
Published: (2020-10-01)

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
by: Hye In Kim, et al.
Published: (2018-01-01)

Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma
by: Aruna Nambirajan, et al.
Published: (2019-01-01)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017-07-01)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
by: Maria A Papadaki, et al.
Published: (2020-06-01)

Immunotherapy Advances in Small Cell Lung Cancer
by: Yangyang XU, et al.
Published: (2020-11-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
by: Seigo Katakura, et al.
Published: (2020-10-01)

Effect and biomarker of Nivolumab for non–small-cell lung cancer
by: Li Wang, et al.
Published: (2019-09-01)

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Emmanuel Acheampong, et al.
Published: (2020-10-01)

Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma
by: Kyu Seo Kim, et al.
Published: (2018-04-01)

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis
by: Yichao Geng, et al.
Published: (2021-02-01)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
by: Jianjun Jin, et al.
Published: (2018-10-01)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
by: Seongho Park, et al.
Published: (2020-02-01)

First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
by: Ling Peng, et al.
Published: (2021-06-01)

IMMUNOHISTOCHEMICAL APPROACH TO DIFFERENTIAL DIAGNOSIS OF NON-SMALL CELL LUNG CARCINOMA IN BRONCHOSCOPIC BIOPSY SPECIMENS
by: Žaklina Mijović, et al.
Published: (2016-06-01)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
by: Giuseppe Bronte, et al.
Published: (2021-05-01)

Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors  of Small Cell Lung Cancer
by: Yaning YANG, et al.
Published: (2020-10-01)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
by: Jongmin Lee, et al.
Published: (2019-01-01)

Immunochistochemical Characteristic of the Microenvironment in Squamous Cell Lung Cancer
by: M. M. Baudarbekova, et al.
Published: (2017-08-01)

Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
by: Sunhee Chang, et al.
Published: (2019-11-01)

A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature
by: Andrew T. Mertz, et al.
Published: (2016-12-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
by: Yixin Zhou, et al.
Published: (2020-03-01)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
by: Yixin Zhou, et al.
Published: (2018-12-01)

Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
by: El-Osta HE, et al.
Published: (2016-08-01)

A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer
by: Prabhakaran S, et al.
Published: (2019-09-01)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
by: Qi Xiong, et al.
Published: (2021-07-01)

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients
by: Wenbin Li, et al.
Published: (2019-02-01)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
by: Ding X, et al.
Published: (2019-05-01)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
by: Jossie Rotman, et al.
Published: (2020-12-01)

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
by: Marta Zayas-Soriano, et al.
Published: (2021-01-01)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
by: Lin Zhang, et al.
Published: (2020-11-01)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
by: Max Hardy-Werbin, et al.
Published: (2019-06-01)

The Incidence of Cystic Fibrosis in the Central Region of Anatolia in Turkey Between 2015 and 2016
by: Songül Şahin, et al.
Published: (2019-05-01)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
by: Trine Vilsbøll Larsen, et al.
Published: (2019-06-01)

Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
by: Bade, R.M, et al.
Published: (2022)

Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
by: Jiyoung Yoon, et al.
Published: (2020-04-01)

Expression of p63 as predictive and prognostic factor in advanced non-small-cell lung cancer
by: Cvetković Gordana, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_8ovnk8f4ajnuuv3lr7v1m4vde5